Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising the recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.

Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.

Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.

Abstract: The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.

Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.

Abstract: We have constructed a mutant EHV-1 that is lacking the entire 12.7 kbp IR segment of the viral genome and found the mutant EHV-1 to be replication competent, to have the ability to replicate in mammalian cell types (including human cells), and to exhibit reduced virulence in the mouse model of EHV-1 virulence.

Abstract: The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.

Abstract: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.

Abstract: Provided are compositions and methods for treatment and/or prophylaxis of EHV-I infections in horses. The compositions and methods effect treatment and/or prophylaxis of EHV-I infections through RNAi mediated inhibition of EHV-I gB and EHV-I Ori genes, which results in a reduction of the severity of neurological symptoms that are induced by EHV-I infection in horses, and/or a reduction in EHV-I viral shedding in the horses. Included are siRNAs or shRNAs that are designed to target EHV-I gB and EHV-I Ori helicase mRNAs. Also included are vectors encoding such shRNAs.

Abstract: The invention belongs to the field of animal health, in particular equine diseases caused by equine herpesvirus (EHV). The invention relates to artificial chromosomes comprising the genome of equine herpesviruses, methods of producing attenuated or virulent EHV with or without the insertion of foreign genes, EHV obtainable with said methods and pharmaceutical compositions comprising said viruses.

Abstract: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.

Abstract: The invention belongs to the field of animal health, in particular equine diseases caused by equine herpesvirus (EHV). The invention relates to artificial chromosomes comprising the genome of equine herpesviruses, methods of producing attenuated or virulent EHV with or without the insertion of foreign genes, EHV obtainable with said methods and pharmaceutical compositions comprising said viruses.

Abstract: The present invention relates to animal viruses such as animal herpesviruses as a vector for diagnostic, therapeutic and prophylactic delivery of foreign genes and nucleic acids to animals, human or primary cells derived thereof, respectively. By using said viruses, the prevention and treatment of infectious, autoimmune and tumor diseases as well as allergies and genetic disorders can be treated. The present invention relates further to procedures to efficiently transduce primary human cells with recombinant animal viruses in vitro and in vivo. The invention further relates to a kit useful (i) for diagnosis and monitoring of innate and adoptive immune responses as well as (ii) for gene therapy and (iii) immunization purposes.

Abstract: Provided is a method for producing a continuous cell line capable of supporting the growth of a Marek's disease virus (MDV) strain comprising infecting or transfecting a cell with a vector comprising a nucleic acid or fragment thereof of an MDV strain and culturing the cell or a progeny thereof under conditions suitable for the expression of the nucleic acid and propagation of the cell or progeny. The nucleic acid may comprise an MDV glycoprotein gE gene or functional fragment. Also provided is a method of generating, isolating, and/or maintaining a hypervirulent, very virulent, very virulent plus, virulent, and/or avirulent MDV strain comprising infecting a described cell with the MDV strain or strains, and culturing the cell under conditions suitable for the propagation of the cell and the generation, maintenance and isolation of the MDV strain or strains.

Abstract: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.

Abstract: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.

Abstract: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.

Abstract: The invention belongs to the field of animal health, in particular equine diseases caused by equine herpesvirus (EHV). The invention relates to artificial chromosomes comprising the genome of equine herpesviruses, methods of producing attenuated or virulent EHV with or without the insertion of foreign genes, EHV obtainable with said methods and pharmaceutical compositions comprising said viruses.